Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Obicetrapib with Midazolam and Digoxin
NCT02124954Phase 1Completed
- Sponsor
- Xention Ltd.
- Start
- May 2014
- Primary completion
- Jul 2014
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of obicetrapib in dyslipidemia (2 arms), sponsored by Xention Ltd. Primary endpoint: Plasma concentrations of TA-8995, midazolam and digoxin. Started May 2014; status: completed.
02
Drugs
obicetrapib
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT02124954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02124954.